Amgen Inc. (AMGN) News Nov 18, 2014, 6:17 p.m. Ma
Post# of 250602
Posted On: 11/18/2014 9:38:09 PM
Amgen Inc. (AMGN) News Nov 18, 2014, 6:17 p.m.
MarketWatch News on AMGN
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Amgen GAAP net of $1.61 is below $1.81 view 4:06 p.m. Oct. 27, 2014 - Russ Britt
Loading more headlines...
Advertisement
Other News on AMGN
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Today - Seeking Alpha
Zetia Shows Modest Benefit in Reducing Heart Attacks 5:26 p.m. Nov. 17, 2014 - The Wall Street Journal Interactive Edition
Merck Drug Works: Vytorin Study Proves Successful 12:35 p.m. Nov. 17, 2014 - Investors Business Daily
3 Stocks Moving The Drugs Industry Upward 12:03 p.m. Nov. 17, 2014 - TheStreet.com
Jana Partners 13F Filing Shows Moves In Alibaba & Other Big Names 10:34 a.m. Nov. 14, 2014 - benzinga.com
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences 9:23 a.m. Nov. 14, 2014 - Seeking Alpha
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog 5:10 p.m. Nov. 13, 2014 - Zacks.com
Amgen Shares Consolidating Ahead Of More Gains? 12:25 p.m. Nov. 13, 2014 - benzinga.com
3 Stocks Underperforming Today In The Drugs Industry 12:06 p.m. Nov. 13, 2014 - TheStreet.com
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination 9:52 a.m. Nov. 13, 2014 - Seeking Alpha
10 Must-Own Stocks With Great Earnings, Sales and Guidance 12:15 a.m. Nov. 13, 2014 - InvestorPlace.com
3 Stocks Reiterated As A Buy: CMCSA, MO, AMGN 1:44 p.m. Nov. 12, 2014 - TheStreet.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New Drugs 8:17 a.m. Nov. 12, 2014 - benzinga.com
Biotech Short Interest Becomes Stock Specific 8:11 a.m. Nov. 12, 2014 - 247WallSt.com
Earnings Triple Plays 2:54 a.m. Nov. 12, 2014 - Seeking Alpha
Amgen's brodalumab beats Stelara in Phase 3 trial 4:52 p.m. Nov. 11, 2014 - Seeking Alpha
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3:03 p.m. Nov. 11, 2014 - benzinga.com
Amgen Fights To Protect Neupogen's Exclusivity 12:31 p.m. Nov. 11, 2014 - Seeking Alpha
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog 11:50 a.m. Nov. 11, 2014 - Zacks.com
Loading more headlines...
Press Releases on AMGN
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Today - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire
Amgen To Present At The Jefferies Global Healthcare Conference 4:15 p.m. Nov. 14, 2014 - PR Newswire - PRF
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver 9:31 a.m. Nov. 13, 2014 - PR Newswire - PRF
Biothera Names Carey Anderson VP of Regulatory Affairs 9:30 a.m. Nov. 13, 2014 - BusinessWire - BZX
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions 4:35 p.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab 4:01 p.m. Nov. 12, 2014 - PR Newswire - PRF
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide 9:00 a.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 11, 2014 - PR Newswire - PRF
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth 2:24 p.m. Nov. 10, 2014 - PR Newswire - PRF
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 9:23 a.m. Nov. 10, 2014 - ACCESSWIRE
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab 9:15 a.m. Nov. 10, 2014 - PR Newswire - PRF
Ziarco Raises $33.1 Million in Series B Financing 7:01 a.m. Nov. 10, 2014 - GlobeNewswire
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Amgen To Present At The Credit Suisse Annual Healthcare Conference 4:30 p.m. Nov. 6, 2014 - PR Newswire - PRF
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 4:01 p.m. Nov. 6, 2014 - PR Newswire - PRF
Cloud Pharmaceuticals Announces World-Class Board of Directors 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer 9:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Karyopharm Appoints J. Scott Garland to Its Board of Directors 7:00 a.m. Nov. 4, 2014 - GlobeNewswire
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model 5:30 a.m. Nov. 3, 2014 - BusinessWire - BZX
Loading more headlines...
MarketWatch News on AMGN
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Amgen GAAP net of $1.61 is below $1.81 view 4:06 p.m. Oct. 27, 2014 - Russ Britt
Loading more headlines...
Advertisement
Other News on AMGN
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Today - Seeking Alpha
Zetia Shows Modest Benefit in Reducing Heart Attacks 5:26 p.m. Nov. 17, 2014 - The Wall Street Journal Interactive Edition
Merck Drug Works: Vytorin Study Proves Successful 12:35 p.m. Nov. 17, 2014 - Investors Business Daily
3 Stocks Moving The Drugs Industry Upward 12:03 p.m. Nov. 17, 2014 - TheStreet.com
Jana Partners 13F Filing Shows Moves In Alibaba & Other Big Names 10:34 a.m. Nov. 14, 2014 - benzinga.com
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences 9:23 a.m. Nov. 14, 2014 - Seeking Alpha
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog 5:10 p.m. Nov. 13, 2014 - Zacks.com
Amgen Shares Consolidating Ahead Of More Gains? 12:25 p.m. Nov. 13, 2014 - benzinga.com
3 Stocks Underperforming Today In The Drugs Industry 12:06 p.m. Nov. 13, 2014 - TheStreet.com
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination 9:52 a.m. Nov. 13, 2014 - Seeking Alpha
10 Must-Own Stocks With Great Earnings, Sales and Guidance 12:15 a.m. Nov. 13, 2014 - InvestorPlace.com
3 Stocks Reiterated As A Buy: CMCSA, MO, AMGN 1:44 p.m. Nov. 12, 2014 - TheStreet.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New Drugs 8:17 a.m. Nov. 12, 2014 - benzinga.com
Biotech Short Interest Becomes Stock Specific 8:11 a.m. Nov. 12, 2014 - 247WallSt.com
Earnings Triple Plays 2:54 a.m. Nov. 12, 2014 - Seeking Alpha
Amgen's brodalumab beats Stelara in Phase 3 trial 4:52 p.m. Nov. 11, 2014 - Seeking Alpha
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3:03 p.m. Nov. 11, 2014 - benzinga.com
Amgen Fights To Protect Neupogen's Exclusivity 12:31 p.m. Nov. 11, 2014 - Seeking Alpha
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog 11:50 a.m. Nov. 11, 2014 - Zacks.com
Loading more headlines...
Press Releases on AMGN
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Today - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire
Amgen To Present At The Jefferies Global Healthcare Conference 4:15 p.m. Nov. 14, 2014 - PR Newswire - PRF
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver 9:31 a.m. Nov. 13, 2014 - PR Newswire - PRF
Biothera Names Carey Anderson VP of Regulatory Affairs 9:30 a.m. Nov. 13, 2014 - BusinessWire - BZX
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions 4:35 p.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab 4:01 p.m. Nov. 12, 2014 - PR Newswire - PRF
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide 9:00 a.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 11, 2014 - PR Newswire - PRF
Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth 2:24 p.m. Nov. 10, 2014 - PR Newswire - PRF
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 9:23 a.m. Nov. 10, 2014 - ACCESSWIRE
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab 9:15 a.m. Nov. 10, 2014 - PR Newswire - PRF
Ziarco Raises $33.1 Million in Series B Financing 7:01 a.m. Nov. 10, 2014 - GlobeNewswire
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Amgen To Present At The Credit Suisse Annual Healthcare Conference 4:30 p.m. Nov. 6, 2014 - PR Newswire - PRF
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 4:01 p.m. Nov. 6, 2014 - PR Newswire - PRF
Cloud Pharmaceuticals Announces World-Class Board of Directors 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer 9:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Karyopharm Appoints J. Scott Garland to Its Board of Directors 7:00 a.m. Nov. 4, 2014 - GlobeNewswire
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model 5:30 a.m. Nov. 3, 2014 - BusinessWire - BZX
Loading more headlines...
(0)
(0)Scroll down for more posts ▼